Patients with melanoma and small cell lung cancer will be the first to receive it.

The choice of these types of cancer is determined by the peculiarities of the study: melanoma is visible on the skin, which simplifies monitoring the effect of the vaccine, and small cell lung cancer is one of the most common and deadly.

The vaccine, developed jointly with several Russian scientific centers, is personalized, that is, it is created individually for each patient.

Preclinical trials of the vaccine have already been completed.

@highlylikely20